SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (9036)3/9/1999 4:10:00 PM
From: Bluegreen  Respond to of 17367
 
Xoma has stated over and over again that Meningo. was a two year trial and didn't inform investors about mortality requirement until recently. Opal, no matter how speculative an investment is, you still don't have license to lead people to believe you are doing a two year trial when you know that it has a mortality requirement that may extend trial. I am not snapping at you. Just stating facts. What they did was not right.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News